



Quinolones and Folic Acid Antagonists

Pharmacology and Toxicology

General Pharmacology

Second Year Medical Students

Tareq Saleh

Faculty of Medicine

The Hashemite University


Textbook: Chapter 31 pp 400-412




Fluoroquinolones



Quinolones



Nalidixic acid



Ciprofloxacin

FLUOROQUINOLONES

Ciprofloxacin CIPRO

Levofloxacin LEVAQUIN

Moxifloxacin AVELOX


Nalidixic acid

Norfloxacin NOROXIN

Ofloxacin





DNA Supercoiling






DNA Helicase








DNA Gyrase





Topoisomerase IV






Quinolones

Mechanism of action

- Inhibit ligation step of bacterial DNA gyrase and bacterial topoisomerase IV

-Inhibition of gyrase: increases the number of permanent chromosomal breaks

-Inhibition of topo IV: interferes with the separation of newly replicated DNA





Quinolones

Mechanism of action

In gram-negative: inhibition of gyrase > topo IV

In gram-positive: inhibition of topo IV > gyrase

What does that mean?



Quinolones

Antibacterial spectrum

- Bactericidal
- Time-dependent killing
- Effective against gram-negative (including E.coli and Pseudomonas), atypical, gram-positive (strep), mycobacteria....
- Levofloxacin: excellent activity against *S. pneumoniae*



Quinolones

Antibacterial spectrum

- **First-generation (nonfluorinated): nalidixic acid**
 - narrow-spectrum
 - **Second-generation: ciprofloxacin and norfloxacin**
 - gram-negative (pseudomonas, H.influenzae) and atypical
 - **Third-generation: levofloxacin**
 - gram-negative, atypical and gram-positive (including S. pneumoniae and MSSA)
 - **Fourth-generation: moxifloxacin, Gemifloxacin, delafloxacin**
 - enhanced gram-positive effects including staph and strep + coverage of gram-negative Enterobacteriaceae
- Homework: Which fourth-generation fluoroquinolone is effective against MRSA?**



Examples of Clinically Useful Fluoroquinolones

Ciprofloxacin

- Effective against gram-negative including *P. aeruginosa*
- Clinical indications:
 1. Gastroenteritis e.g., traveler's diarrhea
 2. Typhoid fever
 3. Anthrax (drug of choice)
 4. Urinary tract infections(high dose for pseudomonal infections)



Examples of Clinically Useful Fluoroquinolones

Levofloxacin

- Similar to cipro but also effective against gram-positive (strep not staph)
- Clinical indications:

First-line therapy for community acquired-pneumonia




Examples of Clinically Useful Fluoroquinolones

Moxifloxacin

- Effective against gram-negative, *S. pneumonia* and mycobacterium
- Clinical indications:
 1. For community-acquired but not nosocomial pneumonia (weak against pseudomonas)
 2. Second-line for TB



Clinical Uses of Fluoroquinolones





Fluoroquinolones and UTIs

“Fluoroquinolones (eg, ofloxacin, ciprofloxacin, levofloxacin) are highly effective in UTIs, but these agents have a propensity for causing collateral damage and should be reserved for important uses other than acute uncomplicated cystitis. IDSA guidelines recommend that fluoroquinolones be used as second-line agents for acute uncomplicated cystitis and as first-line oral therapy for complicated cystitis”.

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Fluoroquinolones

Mechanisms of resistance

-mainly chromosomal

- **Altered target:**

-mutations in *gyrA* or *parC*

- **Decreased accumulation**


-porin channels

-efflux pumps


- **Fluoroquinolone degradation**

- **Cross-resistance**

B. Chromosomally-Encoded Ciprofloxacin Resistance Mechanisms



C. Plasmid-Borne Ciprofloxacin Resistance Mechanisms





Fluoroquinolones

Pharmacokinetics

• Absorption


- mainly oral – IV/ophthalmic preps of cipro and levo
- food, Ca^{++} , Al^{+3} and Mg^{++} interfere with absorption

• Distribution

- very well distributed (high conc in bone, urine and lung)
- good CSF distribution
- concentrate in macrophages and neutrophils

90% bioavailability

20-80% are protein-bound





Fluoroquinolones


Pharmacokinetics

• Absorption

- mainly oral – IV/ophthalmic preps of cipro and levo
- food, Ca^{++} , Al^{+3} and Mg^{++} interfere with absorption

• Distribution

- very well distributed (high conc in bone, urine and lung)
- good CSF distribution
- concentrate in macrophages and neutrophils





Fluoroquinolones

Pharmacokinetics

- **Elimination**

- most fluoroquinolones are excreted renally

- Moxifloxacin is excreted by liver (can be used in patients with renal impairment)



Quinolones

Adverse effects

-generally well-tolerated

- **N/V/D**
- **Headache and dizziness**
- **Peripheral neuropathy and glucose dysregulation**
- **Phototoxicity**
- **(boxed warning) Articular cartilage erosion, tendinitis, tendon rupture**
- **QT prolongation**

Diarrhea




Nausea



Headache



Dizziness



Tendon rupture






Quinolones

Drug-drug interaction

- Cipro can inhibit metabolism of theophylline, others
- Quinolones can raise serum warfarin






Folate Antagonists



Folic Acid Antagonists

- Purine and pyrimidine synthesis requires folate-derived cofactors
- Folic acid is necessary for DNA replication and cellular growth
- Many bacteria are impermeable to folate → rely on de novo synthesis
- Folic acid must be converted into tetrahydrofolate






Sulfonamides



Sulfonamides

Mechanism of action:

- Sulfonamides are synthetic analogues of PABA
- PABA is used to synthesize dihydrofolate
- Sulfonamides inhibit *dihydropteroate synthetase*
- Bacteriostatic





Sulfonamides

Antibacterial spectrum

- Effective against Enterobacteriaceae causing UTIs
- Effective against H. influenza, streptococcus, staphylococcus spp.

Mechanisms of resistance

- Altered dihydropteroate synthetase
- Decreased cellular permeability
- Enhanced production of PABA

INHIBITORS OF FOLATE SYNTHESIS

Mafenide SULFAMYLON

Silver sulfadiazine SILVADENE

Sulfasalazine AZULFIDINE




Sulfonamides

Pharmacokinetics

- **Absorption**

-oral: well-absorbed (except sulfasalazine)

-how can you use sulfasalazine?






Special Uses

TOXOPLASMOSIS RX

First Line

- Pyrimethamine (200mg-L/75C) + Sulfadiazine(6-8g/d -4d/d) till improve CD4 count
- Pyrimethamine + Clindamycine






Sulfonamides

Pharmacokinetics

• Distribution

- highly-bound to serum albumin
- distribute well through body fluids including CSF
- cross placenta
- eliminated in breast milk





Sulfonamides

Pharmacokinetics


• Metabolism

-metabolized in the liver (acetylation and conjugation)

-acetylated metabolites can crystallize in urine causing renal stones

• Elimination

-eliminated by glomerular filtration and secretion





Sulfonamides

Adverse effects

- **Crystalluria**

- nephrotoxicity


- requires adequate hydration and urine alkalinization

- **Hypersensitivity**


- sulfa allergies

- **Hematopoietic disturbances:**


- hemolytic anemia in patients with G6PD deficiency



Crystalluria



Hypersensitivity



Hemolytic anemia



Sulfonamides

Adverse effects

- **Kernicterus**

- in newborns

- sulfa displace protein-bound bilirubin in plasma


- **Drug-drug interaction**

- increase anticoagulant effect of warfarin

- **Contraindications**


- newborn, infants, breastfeeding women

- with methenamine



Kernicterus

Sulfonamides



Methenamine




Trimethoprim



Trimethoprim

Mechanism of action

- Dihydrofolate is reduced to tetrahydrofolate (active form of folate) by dihydrofolate reductase
- Trimethoprim inhibits dihydrofolate reductase
- Decreases purine and pyrimidine synthesis
- Bacterial vs mammalian selectivity
- Mostly combined with sulfa drugs





Trimethoprim

Antibacterial spectrum

- Similar to sulfa drugs e.g., sulfamethoxazole
- More potent as a single agent
- Can be used alone. For what? ... but not very often...

Mechanisms of resistance

- Altered dihydrofolate reductase
- Efflux pumps



Trimethoprim


Adverse effects

- can produce the effects of folic acid deficiency.
 - megaloblastic anemia
 - leukopenia
 - granulocytopenia,
- ***Reversed by administration of folinic acid, which does not enter bacteria.
- Hyperkalemia



Trimethoprim/Sulfamethoxazole (Cotrimoxazole)

- The combination has a synergistic effect
- inhibition of two sequential steps in the synthesis of tetrahydrofolic acid.






Trimethoprim/Sulfamethoxazole (Cotrimoxazole)

Antibacterial spectrum

- Effective in treating UTIs and RTIs
- Effective against *Pneumocystis jirovecii* pneumonia
- Skin and soft tissue MRSA infections
- Drug of choice for infections caused by *Nocardia* spp.



Trimethoprim/Sulfamethoxazole (Cotrimoxazole)






Trimethoprim/Sulfamethoxazole (Cotrimoxazole)

Pharmacokinetics

- Administered orally (IV reserved for severe cases of PCP)
- Crosses BBB
- Excreted in the urine





Trimethoprim/Sulfamethoxazole (Cotrimoxazole)

Adverse effects

- N/V/D
- Skin reactions
- Glossitis/stomatitis
- Hyperkalemia
- Megaloblastic anemia
- Hemolytic anemia in patients with G6PD def
- Drug-drug interaction with warfarin


Skin rash



Nausea



Hematologic toxicities





Urinary Tract Antiseptics/Antimicrobials

- UTIs are more prevalent in women and elderly
- Most common cause: *E. coli* (80% of uncomplicated UTIs)
- Second most common cause: *Staphylococcus saprophyticus*


Most frequently used agents:

- 1. Cotrimoxazole**
- 2. Nitrofurantoin**
- 3. Fluoroquinolones**
- 4. Methenamine**



Methenamine

- **MOA:** decomposes at an acidic pH of 5.5 or less in the urine → produces formaldehyde → toxic to most bacteria
- **Antibacterial spectrum:** used for chronic suppressive therapy to reduce UTIs
- Some activity against *Pseudomonas* or *Proteus* spp





Nitrofurantoin

- Nitrofurantoin is now first-line for uncomplicated cystitis
- **MOA:** Major inhibitor of DNA and RNA synthesis
- Useful against *E.coli*
- Can also cause hemolytic anemia in patients with G6PD
- Should not be used in patients with renal impairment or term pregnant women